MENU
CH | CHF
-
-
-
-
- WHX Labs Dubai 2026
- analytica 2026
- Forum Labo 2026
- SLAS Europe 2026
- Forum Labo 2026 Bioprocess
- Bioprocessing Summit Europe 2026
- BioProcess International 2026
- Swiss Biotech Day 2025
- ISCT 2026
- Pichia 2026
- Future Labs Live 2026
- BioProScale Sympposium 2026
- ASGCT 2026
- Eppendorf Automation Forum 2026
- ESACT 2026
- ELRIG Drug Discovery 2026
-
-
-
-
- WHX Labs Dubai 2026
- analytica 2026
- Forum Labo 2026
- SLAS Europe 2026
- Forum Labo 2026 Bioprocess
- Bioprocessing Summit Europe 2026
- BioProcess International 2026
- Swiss Biotech Day 2025
- ISCT 2026
- Pichia 2026
- Future Labs Live 2026
- BioProScale Sympposium 2026
- ASGCT 2026
- Eppendorf Automation Forum 2026
- ESACT 2026
- ELRIG Drug Discovery 2026
CH | CHF
-
- Pipettes, distributeurs et dispositifs de manipulation de liquides automatisée
- Pipettes mécaniques
- Pipettes électroniques
- Pipettes multicanaux
- Pipettes et distributeurs à déplacement positif
- Distributeurs sur flacon
- Auxiliaires de pipetage
- Accessoires pour pipettes et distributeurs
- Pipetage automatisé
- Consommables d’automatisation
- Accessoires d’automatisation
- Services pour pipettes et distributeurs
Sorry, we couldn't find anything on our website containing your search term.
Sorry, we couldn't find anything on our website containing your search term.
- Page d'accueil
- Lab Academy
- Applied Industries
- Pharma
- CAR-T
- Product solutions CAR-T-cells research workflow
CAR-T Cell Research and Development
Well thought-out tools for pharmaceutical and biotech laboratories
Read more
Read less
Product Solutions for the CAR-T Cell Research Workflow
CAR-T cells, genetically engineered and equipped with specific receptors to target and combat cancer cells, are primarily divided into two categories: autologous and allogenic CAR-T cells. Hereby, autologous CAR-T cells derive from the patient’s own white blood cells and are reintroduced after modification, whereas allogenic CAR-T cells are designed as off-the-shelf solutions for use in different patients. However, both approaches have their challenges. The manufacturing process for autologous CAR-T cells is complex and costly, as each patient’s cells must be individually processed. Allogeneic CAR-T cells, on the other hand, currently do not have the same safety profile, necessitating further research to address these issues.
Lire la suite
ADVANCING CAR-T CELL RESEARCH: FROM PBMC ISOLATION TO LARGE-SCALE PRODUCTION
Lire la suite
*All products are for Research Use Only (RUO).
Lire la suite
Downloads
Brochure
PDF
Resource Guide
PDF
White Paper
PDF